GO:0031802 type 5 metabotropic glutamate receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0031802 describes the molecular function of binding to the type 5 metabotropic glutamate receptor (mGlu5), a G protein-coupled receptor that modulates glutamatergic signaling [1,2].
• mGlu5 binding is studied using radioligands, fluorescent allosteric modulators, and genetic models to probe receptor availability in brain disorders [1,4,5,6,8].
• Altered mGlu5 binding is implicated in epilepsy, nicotine dependence, and psychostimulant sensitization, making it a target for PET imaging and drug development [1,4,5,6].
• Key research tools include mGlu5 knockout mice, point-mutant receptors, and fluorescent negative allosteric modulators for cellular assays [2,8].
• CRISPR-based knockout, knock-in, and overexpression models enable causal interrogation of mGlu5 binding in disease-relevant cell types [3,8].
• EDITGENE provides custom cell models and screening services to accelerate mGlu5 binding research.
Description
The type 5 metabotropic glutamate receptor (mGlu5) is a G protein-coupled receptor that binds glutamate and modulates intracellular calcium mobilization and neuronal excitability [2,3]. The Gene Ontology molecular function term GO:0031802, type 5 metabotropic glutamate receptor binding, describes the binding of a ligand or protein to mGlu5, a critical interaction for understanding glutamatergic signaling in health and disease [1,2]. This term is distinct from receptor activation and encompasses allosteric and orthosteric binding events that regulate receptor function [2,8]. Researchers study mGlu5 binding to elucidate mechanisms of synaptic plasticity, drug addiction, and epilepsy, using techniques such as radioligand binding assays and positron emission tomography (PET) [1,4,5,6]. The availability of mGlu5 binding sites is altered in several neurological conditions, highlighting its clinical relevance [4,5,6]. Understanding GO:0031802 facilitates the development of targeted therapies and diagnostic tools [1,8].
type 5 metabotropic glutamate receptor binding At A Glance
| GO ID | GO:0031802 |
|---|---|
| GO term | type 5 metabotropic glutamate receptor binding |
| Ontology | molecular_function |
| Synonym | type 5 metabotropic glutamate receptor ligand |
| Major function | Binding to mGlu5, a G protein-coupled receptor that modulates glutamatergic neurotransmission |
| Related receptor | GRM5 (metabotropic glutamate receptor 5) |
| Common ligands | Glutamate, allosteric modulators (e.g., MPEP, fenobam), fluorescent negative allosteric modulators |
| Associated diseases | Epilepsy, nicotine dependence, psychostimulant sensitization |
| Research methods | Radioligand binding, PET imaging, fluorescent ligand assays, CRISPR models |
What Is GO:0031802?
GO:0031802 is defined as the molecular function of binding to a type 5 metabotropic glutamate receptor (mGlu5). This term captures the interaction between mGlu5 and any ligand, including endogenous glutamate, synthetic allosteric modulators, or other proteins, without specifying downstream signaling outcomes [2,8]. It is a child of metabotropic glutamate receptor binding and is used to annotate gene products that physically interact with mGlu5.
Why Is type 5 metabotropic glutamate receptor binding Important in Cell Biology?
GO:0031802 is important because mGlu5 binding is a key node in glutamatergic signaling, and its dysregulation is linked to major neurological and psychiatric disorders [1,4,5,6]. Quantifying mGlu5 binding availability using PET or in vitro assays provides biomarkers for epileptogenic zones and treatment response [4,5]. Moreover, allosteric modulators that bind mGlu5 are promising therapeutic candidates, and understanding their binding properties is essential for drug design [2,8]. Thus, research on this term bridges molecular pharmacology, neuroscience, and clinical diagnostics.
• mGlu5 binding is altered in mesial temporal lobe epilepsy and can localize the epileptogenic zone [4,5].
• Long-term nicotine abstinence normalizes mGlu5 binding, suggesting a role in addiction recovery.
• Dextroamphetamine sensitization affects mGlu5 binding availability in mice and humans.
• Biased allosteric agonism at mGlu5 depends on specific binding site residues, informing drug selectivity.
• RGS4 modulates mGlu5-mediated calcium mobilization in astrocytes, linking binding to signaling.
• Fluorescent mGlu5 negative allosteric modulators enable live-cell imaging of receptor binding.
• mGlu5 binding is a target for PET radiotracers in clinical research [1,4,5,6].
• CRISPR knockout of GRM5 provides causal models for studying binding function.
• Point mutations in mGlu5 allosteric sites can dissect binding from activation.
• Overexpression of mGlu5 in cell lines facilitates high-throughput binding assays.
What Happens During type 5 metabotropic glutamate receptor binding?
Ligand recognition and binding site engagement
In simple terms: A ligand docks into a specific pocket on the mGlu5 receptor.
mGlu5 contains a large extracellular Venus flytrap domain where orthosteric agonists like glutamate bind, and a seven-transmembrane domain where allosteric modulators bind [2,8]. Binding at these sites stabilizes distinct receptor conformations, which can lead to biased signaling. Fluorescent negative allosteric modulators have been designed to visualize binding at the allosteric site.
Conformational changes and G protein coupling
In simple terms: Binding causes the receptor to change shape and activate G proteins inside the cell.
Upon ligand binding, mGlu5 undergoes conformational rearrangements that promote coupling to Gq/11 proteins, leading to phospholipase C activation and intracellular calcium release. The efficiency of this coupling can be modulated by binding site occupancy and by regulators such as RGS4.
Modulation by allosteric modulators
In simple terms: Other molecules can bind to different sites and fine-tune the receptor's response.
Positive and negative allosteric modulators bind to the transmembrane domain and alter the receptor's affinity for glutamate or its signaling efficacy [2,8]. Differential contributions of common allosteric binding site residues determine biased agonism, as shown by mutagenesis studies.
Receptor availability and regulation in vivo
In simple terms: The number of receptors available for binding changes with disease or drug exposure.
PET imaging studies using radioligands for mGlu5 have revealed reduced binding availability in the epileptogenic hippocampus of patients with temporal lobe epilepsy [4,5]. Similarly, dextroamphetamine sensitization and nicotine abstinence dynamically regulate mGlu5 binding in vivo [1,6].
Key Genes Involved in GO:0031802 type 5 metabotropic glutamate receptor binding
The following genes and proteins are directly involved in or regulate type 5 metabotropic glutamate receptor binding.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GRM5 | Encodes the type 5 metabotropic glutamate receptor (mGlu5) | Primary target for binding assays and CRISPR models [2,3,8] |
| GNAQ | Gq alpha subunit that couples to mGlu5 | Mediates downstream calcium signaling upon binding |
| GNA11 | G11 alpha subunit that couples to mGlu5 | Alternative G protein for mGlu5 signaling |
| RGS4 | Regulator of G protein signaling 4 | Modulates mGlu5-mediated calcium mobilization in astrocytes |
| HOMER1 | Scaffolding protein that binds mGlu5 | Links mGlu5 to intracellular signaling complexes |
| GRK2 | G protein-coupled receptor kinase 2 | Phosphorylates activated mGlu5, promoting desensitization |
| ARRB1 | Beta-arrestin 1 | Scaffolds mGlu5 and mediates internalization |
| ARRB2 | Beta-arrestin 2 | Regulates mGlu5 trafficking and signaling |
| PRKCA | Protein kinase C alpha | Phosphorylates mGlu5 and modulates binding affinity |
| CALM1 | Calmodulin 1 | Binds mGlu5 C-terminus, regulating receptor function |
| SLC1A2 | Glutamate transporter 1 (GLT-1) | Regulates extracellular glutamate available for mGlu5 binding |
| SLC1A3 | Glutamate transporter 2 (GLAST) | Controls glutamate levels in astrocytes |
| GRIA1 | AMPA receptor subunit 1 | Co-localizes with mGlu5 and modulates synaptic plasticity |
| GRIN1 | NMDA receptor subunit 1 | Functional interplay with mGlu5 in neurons |
| DLG4 | PSD-95 scaffolding protein | Anchors mGlu5 at postsynaptic sites |
| SHANK3 | Scaffolding protein at postsynaptic density | Links mGlu5 to signaling complexes |
| FMR1 | Fragile X mental retardation protein | Regulates mGlu5-dependent protein synthesis |
How Is type 5 metabotropic glutamate receptor binding Regulated?
The binding of ligands to mGlu5 is regulated by multiple mechanisms. Allosteric modulators can enhance or inhibit orthosteric binding by altering receptor conformation [2,8]. RGS4 negatively regulates mGlu5-mediated calcium mobilization in astrocytes, thereby modulating the functional consequences of binding. In vivo, mGlu5 binding availability is dynamically regulated by psychostimulant exposure and nicotine abstinence, as demonstrated by PET imaging [1,6]. Additionally, receptor phosphorylation by GRK2 and PKC can desensitize mGlu5 and reduce binding affinity.
type 5 metabotropic glutamate receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GRM5 | Mesial temporal lobe epilepsy | GRM5 knockout mice, patient-derived iPSC neurons [4,5] |
| GRM5 | Nicotine dependence | GRM5 point-mutant mice, PET imaging |
| GRM5 | Psychostimulant sensitization | GRM5 overexpression in cell lines, behavioral sensitization models |
| RGS4 | Astrocyte calcium signaling | RGS4 knockout astrocytes, calcium imaging |
| GRM5 | Fragile X syndrome | Fmr1 knockout mice, mGlu5 binding assays |
Epilepsy and mGlu5 binding
Reduced mGlu5 binding availability has been observed in the epileptogenic hippocampus of patients with mesial temporal lobe epilepsy, suggesting that mGlu5 PET imaging could help localize the epileptogenic zone [4,5]. In vitro studies confirm decreased receptor availability in epileptogenic tissue.
Addiction and psychostimulant sensitization
Dextroamphetamine sensitization alters mGlu5 binding availability in mice and humans, implicating mGlu5 in psychostimulant-induced neuroadaptations. Long-term nicotine abstinence normalizes mGlu5 binding, indicating a role in addiction recovery.
Astrocyte signaling and RGS4
RGS4 modulates mGlu5-mediated intracellular calcium mobilization in cultured astrocytes, linking mGlu5 binding to glial function and potential neuroinflammatory processes.
From type 5 metabotropic glutamate receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does GRM5 loss affect mGlu5 binding? | GRM5 knockout cell line or mouse |
| How do point mutations in the allosteric site alter binding? | GRM5 point-mutant knock-in cells |
| Can a fluorescent tag track mGlu5 binding in live cells? | Knock-in of fluorescent protein into GRM5 locus |
| Does overexpression of GRM5 increase binding capacity? | GRM5 overexpression stable cell line |
| Which genes regulate mGlu5 binding? | CRISPR library screening in mGlu5-expressing cells |
| Does RGS4 modulate mGlu5 binding? | RGS4 knockout astrocytes |
How to Study the type 5 metabotropic glutamate receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding | Receptor density and affinity | Characterizing allosteric modulators |
| PET imaging | In vivo receptor availability | Epilepsy and addiction studies [1,4,5,6] |
| Fluorescent ligand assay | Real-time binding kinetics | High-throughput screening |
| Calcium mobilization assay | Downstream signaling after binding | Functional characterization |
| CRISPR knockout | Loss-of-function effects on binding | Target validation |
| CRISPR knock-in | Tagged receptor localization | Live-cell imaging |
| RNA-seq | Transcriptional changes | Pathway analysis |
| Proteomics | Protein interaction networks | Identifying binding partners |
Radioligand binding assays
Radioligand binding assays using tritiated or fluorinated ligands quantify mGlu5 binding affinity and density in tissue homogenates or live cells [1,4,5,6]. These assays are foundational for characterizing allosteric modulators.
PET imaging
Positron emission tomography (PET) with mGlu5-selective radiotracers measures receptor availability in vivo, enabling longitudinal studies in animal models and humans [1,4,5,6].
Fluorescent ligand imaging
Fluorescent negative allosteric modulators allow real-time visualization of mGlu5 binding in live cells, facilitating high-content screening.
CRISPR-based genetic models
CRISPR/Cas9 knockout, point mutation, and knock-in of GRM5 or related genes provide causal insights into mGlu5 binding and signaling [3,8].
How CRISPR Can Be Used to Study GO:0031802 type 5 metabotropic glutamate receptor binding
Knockout
CRISPR knockout of GRM5 eliminates mGlu5 expression, providing a null background to study binding specificity and downstream signaling. Knockout astrocytes show altered calcium responses to mGlu5 agonists.
Point Mutation
Point mutations in the allosteric binding site of GRM5 can dissect the contributions of individual residues to biased agonism and binding affinity. Such models are valuable for drug selectivity studies.
Knock-in
Knock-in of fluorescent tags or epitope tags into the endogenous GRM5 locus enables tracking of receptor expression and binding in live cells. This approach preserves native regulation.
Overexpression
Overexpression of GRM5 in heterologous cells increases mGlu5 binding capacity, facilitating high-throughput screening of ligands and allosteric modulators.
How EDITGENE Supports type 5 metabotropic glutamate receptor binding Research
Researchers studying type 5 metabotropic glutamate receptor binding-related genes often need to determine whether a candidate gene is causally involved in receptor availability, signaling, or disease progression. EDITGENE provides custom CRISPR cell models and screening services to address these questions with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for type 5 metabotropic glutamate receptor binding research.
Frequently Asked Questions About type 5 metabotropic glutamate receptor binding
What is GO:0031802?
GO:0031802 is the Gene Ontology molecular function term for binding to a type 5 metabotropic glutamate receptor (mGlu5) [2,8].
What genes are involved in type 5 metabotropic glutamate receptor binding?
The primary gene is GRM5, which encodes mGlu5; interacting proteins include GNAQ, RGS4, HOMER1, and ARRB1/2 [2,3].
How is mGlu5 binding measured?
It is measured using radioligand binding assays, PET imaging, and fluorescent ligand assays [1,4,5,6,8].
What diseases are associated with altered mGlu5 binding?
Altered mGlu5 binding is associated with epilepsy, nicotine dependence, and psychostimulant sensitization [1,4,5,6].
Can CRISPR be used to study mGlu5 binding?
Yes, CRISPR knockout, point mutation, and knock-in models are used to study mGlu5 binding and signaling [2,3,8].
What is the role of RGS4 in mGlu5 binding?
RGS4 modulates mGlu5-mediated intracellular calcium mobilization in astrocytes.
How does dextroamphetamine affect mGlu5 binding?
Dextroamphetamine sensitization alters mGlu5 binding availability in mice and humans.
Does nicotine abstinence change mGlu5 binding?
Long-term nicotine abstinence normalizes mGlu5 binding.
What are fluorescent mGlu5 negative allosteric modulators?
They are chemical probes that bind mGlu5 and emit fluorescence, enabling live-cell imaging of receptor binding.
Where can I get CRISPR cell models for mGlu5 research?
EDITGENE provides custom knockout, point mutation, knock-in, and overexpression cell models for mGlu5 binding studies.
Conclusion
GO:0031802, type 5 metabotropic glutamate receptor binding, is a central molecular function in glutamatergic signaling with broad implications for neurological and psychiatric disorders. Understanding the mechanisms, key genes, and regulatory factors involved in mGlu5 binding can accelerate the development of targeted therapies and diagnostic tools [1,4,5,6,8]. EDITGENE offers comprehensive CRISPR-based solutions to support this research.
References
- 1. Smart K et al.. 2021. Metabotropic glutamate type 5 receptor binding availability during dextroamphetamine sensitization in mice and humans.. J Psychiatry Neurosci 46(1):E1-E13 PMID: 32559027
- 2. Sengmany K et al.. 2020. Differential contribution of metabotropic glutamate receptor 5 common allosteric binding site residues to biased allosteric agonism.. Biochem Pharmacol 177:114011 PMID: 32380090
- 3. Beckers P et al.. 2024. Modulation of Type 5 Metabotropic Glutamate Receptor-Mediated Intracellular Calcium Mobilization by Regulator of G Protein Signaling 4 (RGS4) in Cultured Astrocytes.. Cells 13(4) PMID: 38391904
- 4. Zimmermann M et al.. 2022. Reduced Metabotropic Glutamate Receptor Type 5 Availability in the Epileptogenic Hippocampus: An in vitro Study.. Front Neurol 13:888479 PMID: 35937057
- 5. Lam J et al.. 2019. In vivo metabotropic glutamate receptor type 5 abnormalities localize the epileptogenic zone in mesial temporal lobe epilepsy.. Ann Neurol 85(2):218-228 PMID: 30597619
- 6. Akkus F et al.. 2016. Association of Long-Term Nicotine Abstinence With Normal Metabotropic Glutamate Receptor-5 Binding.. Biol Psychiatry 79(6):474-80 PMID: 25861697
- 8. Fernández-Dueñas V et al.. 2020. Design, Synthesis and Characterization of a New Series of Fluorescent Metabotropic Glutamate Receptor Type 5 Negative Allosteric Modulators.. Molecules 25(7) PMID: 32230915
